“The trend in oncology research continues towards targeted therapies,” said Alberto Gutierrez, Ph.D., director of the Office of In Vitro Diagnostic Device Evaluation and Safety in the FDA’s Center for Devices and Radiological Health. “This test is an example of the important role companion diagnostics play in determining that the safest and most effective treatments are promptly delivered to patients living with serious and life-threatening diseases,” according to an FDA news release from August 2011.
Case studies to be discussed CHI’s conference:
Integrating Companion Diagnostics into Clinical Drug Development:
Hakan Sakul, Ph.D., Executive Director & Head, Diagnostics, Worldwide Research & Development, Clinical Research and Precision Medicine, Pfizer, Inc.
Fully integrating a diagnostic test into crizotinib pivotal trials, leading to a simultaneous submission of a drug-diagnostics combination, presented many challenges as well as opportunities in the development of crizotinib for treatment of NSCLC patients.
Speed of Drug Development by Incorporation of a Companion Test: Crizotinib Case Study
Keith Wilner, Ph.D., Senior Director, Oncology Clinical Development, Pfizer, Inc.
The use of a diagnostic test to appropriately identify a patient population expected to benefit from crizotinib treatment led to smaller clinical trials in NSCLC to meet the primary statistical endpoints as well as a greater chance of successful trials.
Simultaneous Approval of a Therapeutic & Companion Diagnostic: Crizotinib Case Study
Erling Thor Donnelly, Ph.D., R.A.C., Director, Worldwide Regulatory Strategy, Pfizer, Inc.
The simultaneous submission and approval of Pfizer's crizotinib and Abbott Molecular's anaplastic lymphoma kinase (ALK) break-apart FISH companion diagnostic presented unique clinical and regulatory challenges, requiring novel approaches as well as close collaboration between Pfizer, Abbott, CDER, and CDRH.
Early registration discounts are available until November 18, 2011. To view the entire conference agenda and to register, please visit http://www.TriConference.com/
To inquire about sponsoring and/or exhibiting, contact Jon Stroup, 781-972-5483, jstroup@healthtech.com.
Writers and editors are encouraged to attend. To request a press pass, contact Tracey Fielding at tfielding@healthtech.com.
About Cambridge Healthtech Institute (www.chicorporate.com)
Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Barnett International, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech’s Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.
Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business.
Contact:
James Prudhomme
Cambridge Healthtech Institute
781-972-5400
jprudhomme@healthtech.com
